# Eletriptan for the Treatment of Migraine in Patients With Previous Poor Response or Tolerance to Oral Sumatriptan

> **NCT01989936** · PHASE3 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 446 (actual)

## Conditions studied

- Migraine With or Without Aura

## Interventions

- **DRUG:** Placebo
- **DRUG:** Eletriptan 40 mg
- **DRUG:** Eletriptan 80 mg

## Key facts

- **NCT ID:** NCT01989936
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-01
- **Primary completion:** 2000-09
- **Final completion:** 2000-09
- **Target enrollment:** 446 (ACTUAL)
- **Last updated:** 2021-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01989936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01989936, "Eletriptan for the Treatment of Migraine in Patients With Previous Poor Response or Tolerance to Oral Sumatriptan". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01989936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*